$6.31
1.53% today
Nasdaq, Aug 12, 04:21 pm CET
ISIN
US1374041093
Symbol
CADL

Candel Therapeutics Inc Stock price

$6.21
+0.40 6.88% 1M
-2.08 25.09% 6M
-2.47 28.46% YTD
+0.63 11.29% 1Y
+2.96 91.08% 3Y
-0.79 11.29% 5Y
-0.79 11.29% 10Y
-0.79 11.29% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.19 3.16%
ISIN
US1374041093
Symbol
CADL
Industry

Key metrics

Basic
Market capitalization
$331.1m
Enterprise Value
$249.1m
Net debt
positive
Cash
$92.2m
Shares outstanding
49.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.4
Financial Health
Equity Ratio
62.1%
Return on Equity
-83.2%
ROCE
-44.3%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-32.6m | $-37.9m
EBIT
$-33.6m | $-38.2m
Net Income
$-39.6m | $-41.1m
Free Cash Flow
$-27.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
8.7% | -17.1%
EBIT
8.3% | -14.5%
Net Income
-5.9% | 25.5%
Free Cash Flow
15.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.7
FCF per Share
$-0.6
Short interest
17.0%
Employees
42
Rev per Employee
$0.0
Show more

Is Candel Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Candel Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Candel Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
6% 6%
-
- Research and Development Expense 18 18
16% 16%
-
-33 -33
9% 9%
-
- Depreciation and Amortization 1.01 1.01
4% 4%
-
EBIT (Operating Income) EBIT -34 -34
8% 8%
-
Net Profit -40 -40
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Candel Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Candel Therapeutics Inc Stock News

Neutral
GlobeNewsWire
13 days ago
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45...
Positive
Proactive Investors
19 days ago
Candel Therapeutics Inc (NASDAQ:CADL) announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational immunotherapy CAN-2409 for the treatment of pancreatic cancer. The designation adds to CAN-2409's existing Orphan Drug Designation and Fast Track Designation from the US Food and Drug Administration for pancreatic ductal adenocarcinoma.
Neutral
GlobeNewsWire
19 days ago
NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment o...
More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office United States
CEO Paul-Peter Tak
Employees 42
Founded 2002
Website www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today